Johnson & Johnson has initiated a regulatory push in Europe to position its multiple myeloma therapy Tecvayli for earlier use in the treatment sequence. The pharmaceutical giant announced on Tuesday, March 10, 2026, that it has filed an application with the European Medicines Agency (EMA). The submission seeks to expand the drug's label, allowing it to be used as a single-agent treatment for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
The European filing comes just five days after U.S. regulators granted approval for a regimen combining Tecvayli with Darzalex for a similar patient population. This nearly simultaneous transatlantic regulatory activity provides a significant boost to Johnson & Johnson's strategic position in the competitive myeloma market. The company is actively advancing its newer oncology assets to help offset anticipated revenue declines from its blockbuster drug Stelara, which faces increasing biosimilar competition. This pipeline momentum is considered crucial for Johnson & Johnson to remain on track toward its ambitious $100.5 billion sales target for 2026.
Robust Clinical Data Supports Submission
The EMA application is underpinned by results from the Phase 3 MajesTEC-9 clinical trial, which enrolled 614 participants. According to the company, Tecvayli demonstrated a substantial 71% reduction in the risk of disease progression or death compared to standard treatment regimens. Furthermore, the therapy was associated with a 40% lower risk of death in patients whose multiple myeloma had relapsed or become refractory to earlier interventions.
Tecvayli currently holds conditional marketing authorization in Europe as a monotherapy, but for later lines of treatment. The new data has been characterized by experts as a potential turning point. Dr. Roberto Mina of Emory University suggested earlier this year that the drug could become "an essential therapy" even at the first relapse. Johnson & Johnson's own Dr. Jordan Schecter stated that Tuesday's regulatory submission aims to bring the drug's benefits—characterized by deeper and more durable responses—forward in the disease course.
Fast-Tracked U.S. Approval and Competitive Landscape
The U.S. Food and Drug Administration moved swiftly on the combination therapy, granting approval a mere 55 days after the review process began. Dr. Luciano Costa, a trial investigator, described the Tecvayli-Darzalex combination as a development that could "redefine how we approach" relapsed multiple myeloma, a cancer of plasma cells in the bone marrow.
The treatment landscape for multiple myeloma is intensifying. Pfizer's Elrexfio is already available for patients in later lines of therapy. Meanwhile, Bristol Myers Squibb reported on Monday that its investigational mezigdomide regimen met the primary endpoint in a pivotal trial for relapsed myeloma. RBC Capital Markets analyst Trung Huynh noted the mezigdomide program had been "modestly overlooked" prior to the release of more detailed data.
Financial Impact and Market Reaction
The oncology franchise is already a major financial driver for Johnson & Johnson. In 2025, Darzalex generated $14.35 billion in sales, a 23% year-over-year increase, contributing significantly to the company's total revenue of $94.2 billion. The continued growth in oncology helped propel the company's overall performance.
Investors reacted positively to the news, with Johnson & Johnson's stock rising approximately 0.7% during early afternoon trading in New York on Tuesday.
Outstanding Questions and Next Steps
While the filing marks a key step, the regulatory process in Europe is just beginning. The complete dataset from the MajesTEC-9 trial has not yet been presented at a major medical conference, and safety considerations remain a point of discussion. During the U.S. combination trial, investigators noted serious infections and cytokine release syndrome—a potentially severe immune system overreaction—as notable adverse events. Johnson & Johnson maintains that no unexpected safety signals emerged in the monotherapy arm of its studies.
The company's strategic filings in both the U.S. and Europe underscore its commitment to expanding the utility of Tecvayli and strengthening its portfolio against mounting competitive and patent-cliff pressures in the years ahead.
